The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where Ra, R1, R2, R2', R3, R4, X1, X2, X3, X4, Y, Q, Q1, and n are described herein.本發明係關於非全身TGR5促效劑，其適用於治療化學治療誘發之腹瀉、糖尿病、II型糖尿病、妊娠期糖尿病、空腹葡萄糖異常、葡萄糖耐受性異常、胰島素抗性、高血糖症、肥胖症、代謝症候群、潰瘍性結腸炎、克羅恩氏病(Crohn's disease)、尤其在短腸症候群期間與非經腸營養相關之病症及大腸急躁症(IBS)及其他TGR5相關疾病及病症，其具有下式：其中Ra、R1、R2、R2'、R3、R4、X1、X2、X3、X4、Y、Q、Q1及n在本文中加以描述。
